@708 this may assists...CANNTAB PHARMACEUTICALSOn the 8th...

@708 this may assists...

CANNTAB PHARMACEUTICALS

On the 8th January 2018 Cann Global Limited's (formerly QBL) Medical Cannabis Pharmaceutical Division's subsidiary, 'VitaCann' announced that it had signed an exclusive 50/50 joint venture agreement for Australian and International distribution rights to a Pharmaceutical Grade Medical Cannabis Extended Release (XR) pill with Canntab Therapeutics Limited ("Canntab") of Toronto, Ontario, Canada.

Cann Global is pleased to advise on the following updates:

- There have been recent positive developments regarding the export of the Canntab Medical Cannabis Pharmaceutical 'XR' pill to Australia. The company can report that the tablets are now in a legal dosage form following the Health Canada approval in October. The Markham facility which will manufacture the initial production of the tablets is expected to be licensed to produce the tablets within 90 days (by March 2020) with a lead time of 120 days for blister pack orders with exports permitting.

- The company is also in discussion with Canntab to import their new range of Cannabis oil Gel capsules for sale in the Australian and Asian market in January/February 2020. In August 2019 Canntab's Jeff Renwick, the co-founder and CEO of Canntab Therapeutics said in a statement, "We are excited to enter this new phase in our development, with manufacturing beginning in the Cobourg facility and construction nearing completion in Markham, we are taking the final steps necessary to bring our products to market," He went on to add, "Oil-filled gel capsules will represent the first stream of revenue for Canntab before we are able to launch our flagship hard tablet products. Our line of solid oral dosage forms with timed release properties is expected to be the future of medical cannabis".